Christine E. Siu
Independent DirectorMs. Christine E. Siu, M.B.A, is Chief Executive Officer of BridgeBio Neuromuscular of BridgeBio Pharma, Inc. She served as Independent Director of Bright Peak Therapeutics AG since December 2020. She served as Director at Vividion Therapeutics, Inc. since May 2021. She has been an Independent Director at Monte Rosa Therapeutics, Inc. since February 2021. Ms. Siu joined the Monte Rosa Therapeutics, Inc. in February 2021. She served as the Chief Financial Officer at Eidos Therapeutics, Inc. since December 2017 until December 31, 2019, previously as Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. She served as Vice President at Thomas, McNerney & Partners from 2008 to 2010, where she invested in life sciences companies. She served as a Principal at Warburg Pincus LLC, where she invested in Healthcare Services. She was an Analyst in the Health Care Investment Banking Group at The Bear Stearns Companies, LLC. She served as Director of NeuroTherapeutics Pharma, Inc. Ms. Siu is the Chief Operating Officer in Residence of BridgeBio Pharma Inc. since January 2020. Prior to that, Ms. Siu served as the Chief Business Officer of the Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. She is a life sciences industry leader with extensive experience in corporate development, strategy and financial roles. Ms. Siu has a strong track record of creating value and integrating financing strategy with corporate development. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT) since 2012 to 2014 and before that, a Venture Principal at Third Rock Ventures, LLC where she was part of the GBT launch team and first employee at GBT. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and is a BS, with distinction, in Cellular Molecular Biology and Economics from the University of Michigan.
Positions
- Company NameMonte Rosa Therapeutics, Inc.Stock CodeGLUEPositionIndependent DirectorColleagues
- MWMarkus WarmuthPresident, CEO & Director
- ANAndrew Newman SchiffIndependent Chairman of the Board
- PNPhilip NicksonChief Business & Legal Officer
- FJFilip JankuChief Medical Officer
- MBMatthew BowenCorporate Controller & Principal Accounting Officer
- JCJennifer ChampouxChief Operating Officer
- KLKimberly Lynn BlackwellIndependent Director
- JSJan SkvarkaIndependent Director
